Novartis digs deeper in radiopharma with $1.75bn Mariana buy
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
Innovation as Strategy: Enabling life sciences of the future
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
Deep Dive: Market Access 2024
In this edition of Deep Dive, Unpacking complex choreography in the biologics patent dance, Alexion examines the urgent need for accelerated access programmes for rare disease treatments, and Putna
How doctors are interacting with content in 10 data trends
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
Patient Centricity to Integration: Enhancing Cancer Outcomes
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
4th Next Generation Gene Therapy Vectors Summit 2024
Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston), the industry’s only hub for covering the latest advances and innovations in
Final FDA rule on LDTs creates a paradigm shift for laborato...
WASHINGTON, D.C., April 30, 2024 –The Food and Drug Administration’s (FDA) final rule has reclassified laboratory developed tests (LDTs) as medical devices, according to Avalere.